The gist:
• Nicotine bitartrate dihydrate is a nicotine salt used mainly in lozenges and other smoking cessation products, so sourcing depends on documented purity, batch traceability and regulatory compliance.
• A dependable manufacturer should operate under cGMP conditions, provide full raw-material traceability and test every batch against recognised pharmacopoeial standards.
• UK-based buyers typically look for suppliers with established manufacturing history, consistent supply, and clear documentation rather than the lowest quoted price.
Pharmaceutical and nutraceutical formulators searching for a dependable source of this ingredient are generally trying to confirm one thing: whether a supplier’s documentation, testing regime and production history can withstand regulatory scrutiny. A Nicotine Bitartrate Dihydrate Manufacturer is expected to demonstrate consistent batch quality and traceable sourcing before any commercial relationship is considered viable, since the compound is classified as a highly regulated active ingredient rather than a commodity chemical.
Nicotine bitartrate dihydrate is the salt form of nicotine paired with tartaric acid. It is commonly checked against USP and EP reference standards, which confirm identity, purity, and assay results in finished products. The compound is used in lozenges and other oral nicotine replacement formats, so it belongs to pharmaceutical-grade manufacturing rather than general chemical supply. Manufacturers looking for a supplier can Contact BGP Group to learn more about available products and specifications.
Why Sourcing Standards Matter for This Ingredient
Formulators working with nicotine salts are dealing with a substance that carries strict hazard classifications and handling requirements. Reference standard listings for this compound show hazard statements covering acute toxicity by dermal, inhalation and oral routes, which is why documentation and controlled handling matter at every stage of production.
Three factors tend to separate dependable suppliers from inconsistent ones:
• Batch traceability – records that follow raw material through to finished product, not just a certificate of analysis on request.
• Pharmacopoeial alignment – testing against recognised monographs rather than internal-only specifications.
• Manufacturing continuity – a facility with a demonstrated production history, rather than a trading intermediary with no direct control over output.
Core Criteria for Evaluating a Manufacturer
Selecting a supplier of this ingredient involves more than comparing unit prices. The following points reflect what formulators in regulated markets typically assess before committing to a long-term order.
1. Quality control depth – in-process testing at multiple stages, not only a final release check.
2. Regulatory documentation – access to certificates of analysis, safety data sheets, and batch records aligned with pharmacopoeial monographs such as those published by the European Directorate for the Quality of Medicines & HealthCare.
3. Supply consistency – a track record of meeting order volumes without unexplained gaps between batches.
4. Technical responsiveness – the ability to answer specification queries without delay, which matters most during audits or new product qualification.
| Evaluation Area | What to Check | Why It Matters |
| Documentation | Batch records, CoA, SDS | Supports regulatory submissions |
| Testing regime | In-process and final release testing | Confirms purity and consistency |
| Production history | Years of continuous manufacturing | Indicates process stability |
| Supply reliability | Order fulfilment track record | Reduces production downtime risk |
Regulatory Context for UK Buyers
Businesses sourcing nicotine salts in the UK operate within a framework that expects ingredient suppliers to meet Good Manufacturing Practice standards and maintain full batch documentation. This is particularly relevant for nicotine replacement therapy components, where regulatory agencies require consistent specifications across every production run before a finished product can reach the market.
Manufacturing history also carries weight in supplier evaluation. BGP Group is recorded as a nicotine-based API manufacturer with a facility history dating back to 1976, and its product range includes nicotine bitartrate dihydrate alongside other nicotine derivatives used in pharmaceutical formulations.
Frequently Asked Questions
1. What is nicotine bitartrate dihydrate used for?
→ It is primarily used as the active nicotine salt in lozenges and related nicotine replacement formats, where its stability and known molecular weight support consistent dosing.
2. Why does batch traceability matter so much for this ingredient?
→ Because it is classified as a highly regulated substance, any gap in documentation can delay or block regulatory approval for the finished product, making full traceability from raw material to output essential.
3. Is this ingredient the same as nicotine ditartrate dihydrate?
→ Yes, nicotine bitartrate dihydrate and nicotine ditartrate dihydrate refer to the same compound and are often listed as synonyms across pharmacopoeial reference standards.
Final Note on Supplier Selection
Choosing a supplier for this ingredient depends on verifiable documentation and consistent production practice rather than marketing claims. For business location and contact details, view BGP Group on Google Business Profile alongside other supplier records when comparing manufacturing history.
